Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 251 - 260 of 333

<< Previous | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | Next >>

Last updated: 20th February 2008

Patent No.: WO 9964611
Manufacture of an antimicrobial peptide in Escherichia coli as a fusion protein with the purF gene products.
Applicant: Kim JH, Kang MH, Lee J-H, Park SH, Lee JW, Hong SS, Lee H-S (1999)
A method of effective prodn. of an antimicrobial peptide by manuf. as a fusion protein with the purF gene product (glutamine phosphoribosylpyrophosphate amidotransferase) is described. The fusion gene encodes a protein that has an antimicrobial peptide as the N-terminal moiety linked by a peptide contg. proteinase or chem. cleavage sites to all or part of the purF gene products. The fusion gene is terminated with the dual termination codon sequence TAATGA. By transforming E. coli with the expression vectors, the fusion gene under the control of T7 or lacZ promoter was expressed efficiently as a polypeptide which was cleavable to release antimicrobial peptide after purifn. In this way, the antimicrobial peptide can be expressed in E. coli with minimal toxicity and resistant to proteinase degrdn. The tested antimicrobial peptides included frog MSI-344 gene coded protein, and various frog or insects or human or carb peptides with the expression levels in the range of 4% to 35% of E. coli total proteins. The expression level of MSI-344 gene from the vector carrying 4 copies of the fusion genes (tetramer) was increased to 30% to 40% or 20% to 25% resp. in T7 and lacZ promoter constructs compared to that from the vector carrying only a one copy of the fusion gene (monomer). The effective expression of these antimicrobial peptides in E. coli showed the potential of economical mass prodn. of the antimicrobial peptide for therapeutic use.

Patent No.: WO 9959574
A method for stimulation of defensin production by exposure to isoleucine.
Applicant: Fehlbaum P, Anderson M, Zasloff M, Rao M (1999)
The invention relates to a method for the stimulation of defensin prodn. in eukaryotic cells such as, for example, mammalian cells. The method comprises exposing said cells to a compn. comprising isoleucine or active isomers and analogs thereof. Furthermore, the invention includes a method for the prevention and treatment of infections and other various disease states and in the stimulation of the immune system. For screening of compds. that have defensin-inducing activity, a stable cell line expressing the defensin plasmid-luciferase plasmid was constructed and placed in wells of a tissue culture plate. After the test substances had been in contact with the cells for 12-24 h, luciferase expression levels were measured using std. procedures.

Patent No.: WO 9946288
A process for isolating and purifying viruses, soluble proteins and peptides from plant sources including transgenic plants.
Applicant: Garger SJ, Holtz RB, Mcculloch MJ, Turpen TH (1999)
The present invention features a method for isolating and purifying viruses, proteins and peptides of interest from a plant host which is applicable on a large scale. Moreover, the present invention provides a more efficient method for isolating viruses, proteins and peptides of interest than those methods described in the prior art. In general, the present method of isolating viruses, proteins and peptides of interest comprises the steps of homogenizing a plant to produce a green juice, adjusting the pH of and heating the green juice, sepg. the target species, either virus or protein/peptide, from other components of the green juice by one or more cycles of centrifugation, resuspension, and ultrafiltration, and finally purifying virus particles by such procedure as PEG-pptn. or purifying proteins and peptides by such procedures as chromatog. and/or salt pptn. The invention also concerns transgenic plants and the isolation of viral proteins and/or other fusion proteins.

Patent No.: WO 9945152
Methods for identifying polycationic, peptide-like compounds with antibacterial activity.
Applicant: Van Dyk TK, Cajal Y, Jain MK (1999)
A method is provided for identifying polycationic, peptide-like compds. characterized by antibacterial activity against gram neg. bacteria. The method takes advantage of the induction of hyperosmotic stress without leakage of cytoplasmic content. The method involves detg. whether the compd. has the ability to produce phospholipid exchange between the lipid bilayers in conjunction with the induction of the osmotic stress response in the target cell. Detg. the induction of the osmotic stress response is effected using a bioluminescent detector organism having a osmY-LUX gene fusion.

Patent No.: WO 9925835
Sweet tasting protein brazzein fused with membrane target sequence to increase its expression in plants.
Applicant: Drake CR, Osborn RW, Evans IJ, Ray JA (1999)
The levels of protein expression is improved by post-translational transport to a cellular membrane, esp. transport to the extracellular space, by the use of membrane-targeting sequences. One specific use of this invention was in the expression of the DNA coding sequence for the sweet-protein brazzein using several membrane-targeting sequences from Saccharomyces, radish, or dahlia. For example, constructs contg. radish signal peptide fused with the brazzein was expressed in tomato and the level of brazzein expression was greatly increased.

Patent No.: WO 9913886
Antisense oligonucleotides capable of binding to multiple targets and their use in the treatment of respiratory disease.
Applicant: Nyce JW (1999)
Antisense oligonucleotides carrying sequences that will allow them to bind to more than one mRNA in a target cell are described. Such oligonucleotides can be used as a single treatment for diseases having more than one contributing pathway. In particular, oligonucleotides effective against genes involved in the etiol. of respiratory disease are targeted. Preferably, the oligonucleotides are low in adenosine (15%) and may have adenosines substituted with analogs. These oligonucleotides are targeted to high (G+C) sequences within mRNAs. Thus, phosphorothioate antisense oligonucleotide (HAdA1AS, 5'-gatggagggcggcatggcggg-3') designed for the adenosine A1 receptor is provided. HAdA1AS significantly and specifically reduces the in vivo response to adenosine challenge in a dose-dependent manner, is effective in protection against aeroallergen-induced bronchoconstriction (house dust mite), has an unexpected long-term duration of effect (8.3 days for both PC50 adenosine and resistance), and is free of side effects that might be toxic to the recipient. Such oligonucleotides may be used for treating a disease or condition assocd. with lung airway, such as bronchoconstriction, inflammation, or allergies.

Patent No.: WO 9913080
Identification of ZAMP1, a new member of the human beta-defensin family by sequence homology.
Applicant: Adler D, Holloway JL, Baindur N, Beigel S (1999)
ZAMP1, a new member of the human beta-defensin family is identified for therapeutic use and a cDNA encoding it is cloned. The polypeptides, and polynucleotides encoding them, exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The present invention also includes antibodies to the ZAMP1 polypeptides. A cDNA for the protein was identified by querying an EST database for homologs of the defensin SAP-1. A single homolog was identified in a human bronchial epithelium EST library. Primers derived from the EST were used to clone the gene by PCR and a full-length cDNA obtained by std. methods.

Patent No.: US 6008195
Antimicrobial peptides and methods of use.
Applicant: Selsted ME (1999)
Novel antimicrobial peptides from bovine and murine neutrophils are provided. The peptides, designated bovine granulocyte peptide A (BGP-A) and murine granulocyte peptide A (MGP-A) were purified to homogeneity from peripheral blood granulocytes. The amino acid and nucleotide sequence of BGP-A and MGP-A are also provided. A synthetic version of BGP-A and MGP-A is also provided. The purified BGP-A peptide is shown to have antimicrobial activity indistinguishable from that of natural BGP-A. Synthetic carboxamidated analogs of BGP-A (BGP-A-amide) and MGP-A (MGP-A-amide) are also provided.

Patent No.: US 6001805
Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides.
Applicant: Jaynes JM, Julian GR (1999)
A method of treating a wound of a mammalian subject in need of such treatment, to promote healing thereof, comprising administering to the subject, e.g., to the wound locus, a composition comprising a fibroblast and keratinocyte proliferatingly effective amount of an amphipathic peptide, preferably an amphipathic peptide which is antimicrobially effective at such locus. A method is also disclosed of stimulating the accelerated growth of dermal tissue in a tissue culture containing same, comprising applying to the tissue culture a fibroblast and keratinocyte proliferatingly effective amount of an amphipathic peptide, by which the dermal tissue may be grown to produce skin for skin grafting purposes, utilizing a dermal tissue culture containing dermal tissue material of a skin graft recipient of such skin. Novel amphipathic peptides suitable for use in such methods are disclosed.

Patent No.: US 5998698
Transgenic fish capable of expressing exogenous lytic peptides.
Applicant: Cooper RK, Enright FM (1999)
Novel means have been discovered for increasing the resistance of an animal host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. The infection treated may, for example, be equine infectious anemia, or infection by the human immunodeficiency virus. Novel means have also been found for treating tumors. Augmentation of the host's defenses against infectious diseases or tumors is achieved by "arming" the host's cells with an exogenous gene encoding a natural or synthetic lytic peptide. The lytic peptide tested was cecropin B. For example, the transfection of hematopoietic stem cells and embryonic cells will produce animals with enhanced disease resistance; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors. Genes coding for a cecropin or other native or synthetic lytic peptide can be transferred and stably expressed in mammalian, bony fish, other vertebrate, and other animal cells. The transformed cells have the ability to produce and secrete a broad spectrum chemotherapeutic agent that has a systemic effect on certain pathogens, particularly pathogens that might otherwise evade or overcome host defenses.